STAT+: A turning point for pancreatic cancer patients

Chronological Source Flow
Back

AI Fusion Summary

New pancreatic cancer drug offers hope, while ASCO reports darxonrasib results and a Chinese lung cancer therapy surpasses expectations. A decades‑old biohacker peptide sparks FDA regulatory debate, highlighting ongoing biotech challenges.
Community Comments
Loading updates...
0